Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2728 - Evaluation of safety, tolerability and efficacy of Temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice


09 Sep 2017


Poster display session




Martin Dreyling


Annals of Oncology (2017) 28 (suppl_5): v355-v371. 10.1093/annonc/mdx373


M. Dreyling1, G. Hess2, G. Krekeler3

Author affiliations

  • 1 Medizinische Klinik Und Poliklinik Iii, Klinikum der Universität München-Grosshadern, 81377 - Munich/DE
  • 2 Iii. Medizinische Klinik, Universitätsmedizin der Johannes Gutenberg-Universität, 55101 - Mainz/DE
  • 3 Medical, Pfizer - Germany, 10785 - Berlin/DE


Abstract 2728


Temsirolimus (TEM), an mTOR inhibitor, is approved in the EU for the treatment of pts with rel/refr MCL. A pivotal study demonstrated significantly longer progression free survival (PFS) with TEM (175 mg weekly for 3 weeks followed by 75 mg weekly) in rel/refr MCL pts compared to investigatoŕs choice therapy (4.8 vs 1.9 months (mo); P = .0009). To evaluate the safety profile and efficacy of TEM in this rare tumor entity, further data collection in an unselected routine clinical patient population is useful.


A German multicenter registry for rel/refr MCL pts treated with TEM was started in Germany in Oct 2009 with regulatory and ethic committeés approval. Objectives are the evaluation of the safety profile, tolerability and anti-tumor activity of TEM as well as patient's profile including comorbidities, characteristics, and the sequence of systemic therapies.


From Oct 2009 to Feb 2017, 55 pts were recruited in 30 study sites. Baseline characteristics are available for 55 pts: 69.1% male; median age 74.4 years; bone marrow involvement in 38.2% of the pts; ECOG PS (n = 54) 0 or 1 in 83.3%, ECOG PS 2 in 16.7%. According to MIPI score (n = 53), 20.8%, 34.0%, and 45.2% are classified as low, intermediate, and high risk at the time of enrollment. Median number of prior therapies is 2 with 43.6% treated in ≥ 4th line. Most common drug-related toxicities of any grade (incidence ≥ 15%) are observed in following categories: blood/lymphatic system disorders (49.1%), gastrointestinal disorders (27.3%), general disorders (21.8%), and skin/subcutaneous tissue disorders (18.2%). Efficacy analyses are available for 39 assessable pts with an objective response in 30.8%, a clinical benefit (CR, PR, MR and SD) in 59.0% and PD in 41.0% of the pts. Median PFS for all pts is 3.6 mo. For the subgroup of pts treated with TEM in 2nd and 3rd line PFS is 3.3 mo, for ≥ 4th line pts 4.9 mo.


The registry was started to evaluate the safety and efficacy of TEM in pts with rel/refr MCL in routine clinical practice. In this comparatively poor-prognosis patient population, TEM showed a predictable, manageable tolerability profile. Efficacy parameters were consistent with published phase III data.

Clinical trial identification


Legal entity responsible for the study

Pfizer Pharma GmbH


Pfizer Pharma GmbH


M. Dreyling, G. Hess: Consultant Pfizer Pharma GmbH, Honoraria from Pfizer GmbH. G. Krekeler: Employee of Pfizer Pharma GmbH.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.